Results from the Canadian Community Health Survey (CCHS) found that of those Canadians diagnosed with diabetes before the age of 50 years, 63% were South Asians, 57% were Aboriginal, 50% were Chinese, and 35% were self-described as White (Statistics Canada, 2003) . Low socioeconomic status has also been associated with an increase in diabetes prevalence, with estimates at 2.8% among people in the highest income group compared to 3.9% in those in the lowest income group (Rabi, Edwards, Southern, Svenson, Sargious, Norton, et al., 2006). Finally, weight and obesity also increases the risk of diabetes, with the prevalence among underweight or normal weight individuals at 2.7%, 5.7% in those considered overweight, and 12.1% in those considered obese (Statistics Canada, 2003) .
According to PHAC's National Diabetes Surveillance System (NDSS), among adults aged 20 years and older, mortality rates of individuals with diabetes were twice as high, compared to individuals without diabetes (PHAC, 2009a) . Diagnosed diabetes significantly shortened life expectancy for all ages. Women and men with diagnosed diabetes in the 25 to 39 year age groups had about an 8-year reduction in life expectancy (PHAC, 2009a) . In 2005-2006, adults with diagnosed diabetes were hospitalized: a) three times more often with overall cardiovascular disease including, hypertensive disease (1,397,188), heart failure (49,665), heart attack (93,691), ischaemic heart disease (26, 895) , and stroke (23,912); b) seven times more often with chronic kidney disease (40, 341) ; and c) 23 times more often with lower limb amputations, than adults without diabetes (3,001) (PHAC, 2009a). Moreover, as the diagnosis of diabetes is often delayed, 20-50% of people with type 2 diabetes present with microvascular and/or macrovascular complications at the time of diagnosis (Klein, Klein, Moss, et al., 1984; UK Prospective Diabetes Study (UKPDS) Group; 1998).
Etiology and natural history
The development of type 2 diabetes is attributed to beta cell dysfunction (insulin secretion and/or insulin deficiency), and insulin resistance. Pancreatic beta cells initially manage elevated glucose levels by secreting additional insulin. However, insulin secretion eventually fails, leading to impaired glucose tolerance, or prediabetes, and eventually clinical diabetes (Warren, Martin, Kroleswski, et al., 1990; Hamman, 1992) . With the exception of rare forms of type 2 diabetes (e.g. maturity-onset diabetes of the young and diabetes-deafness syndrome) which account for < 1% of all cases of diabetes, most cases of diabetes are related to genes, the environment or both (Capes & Anand, 2001 ).
Type 2 diabetes is often diagnosed 'by chance', usually part of a routine physical examination or during treatment for other conditions. A US National Health Interview Survey found that only one half of the people with type 2 diabetes had symptoms at the time of their diagnosis (Harris, Flegal, Cowie, et al., 1998) . The classic symptoms of diabetes include polydipsia, polyuria and polyphagia. However, other symptoms common with type 2 diabetes include fatigue, blurred vision, infection, recent weight loss, and/or neurologic symptoms in the feet.
The previous notion that type 2 diabetes was exclusively a result of poor lifestyle choices and not an inheritable metabolic disorder was proven otherwise with evidence from monozygotic twins, demonstrating a strong link in heritability, approximately 34-80%, particularly in certain ethnic groups and parents with diabetes (Rewers & Hamman, 1995) . Type 2 diabetes is also determined by a myriad of other lifestyle factors, including body mass index, waist circumference, diet and activity level (Knowler, Barrett-Connor, Fowler, et al., 2002 ; Orozco, Buchleitner, Gimenez-Perez, Roque i Figuls, Richter & Mauricio, 2008) . Evidence for the environment as a determinant of diabetes is also apparent in studies of recent immigrants from a developing country to Canada. Research shows that immigrants to Canada of South Asian background have a 3-4 fold increase risk for diabetes than immigrants from Western Europe or North America (Creatore, et al., 2010; Lipscombe & Hux, 2007) .
Consequences if left untreated
Short term consequences of type 2 diabetes if left untreated include diabetic ketoacidosis (DKA) and hyperosmolar nonketotic state (HNKS). Both acute consequences are rare in type 2 diabetes, but may occur with prolonged hyperglycemia, as a result of a concurrent illness or infection. DKA, typically a consequence in type 1 diabetes, may also be the first manifestation of type 2 diabetes, leading to a diagnosis. The mortality rate of DKA with appropriate management is < 3% (Capes & Anand, 2001) . HNKS may occur with severe hyperglycemia, which leads to hyperosmolality and volume contraction. This life threatening acute complication typically presents in the elderly and despite treatment, has a mortality rate of up to 50% (Capes & Anand, 2001 ).
Long term consequences of type 2 diabetes are often described as microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (cardiovascular disease) complications. Retinopathy, including proliferative retinopathy and macular edema is found in approximately 40% of the U.S. adult diabetes population (Kempen, O'Colmain, Leske, et al., 2004) . Intensive glucose and blood pressure therapy has been proven to prevent the onset and progression of retinopathy (UK Prospective Diabetes Study Group, 1998). Nephropathy, including chronic kidney disease (CKD) and end-stage renal disease (ESRD) are common and potentially devastating complications of diabetes. It is estimated that 50% of people with diabetes have some form of chronic kidney disease (CIHI, 2001 ). The course of nephropathy is a step-wise progression, which begins as a subclinical disease, to the early developing of nephropathy, characterized by microalbuminuria (30-300 mg/24 hours), to eventually overt nephropathy (> 300 mg/24 hours) (Steele, 2001) . To that end, epidemiological data suggests that 10-20% of individuals with diabetes develop ESRD (Ritz & Stefanski, 1996) . Individuals with ESRD are among those at the highest risk for cardiovascular mortality, with a life expectancy of three years after diagnosis (Gerstein, Mann, Yi, et al., 2001 ).
Neuropathy is a likely complication that will develop in 40-50% of individuals within the first 10 years of the onset of diabetes, and is associated with sensory loss, pain and weakness (Dyck, Kratz, Karnes, et al., 1993) . Among the various forms of neuropathy, polyneuropathy, damage to a diffuse set of peripheral nerves, particularly in the feet and legs, is the most common form (Bril & Perkins, 2008) . Neuropathy may then lead to foot ulcers and infections, which may result in lower limb amputation. The onset and progression of neuropathy can be lessened with intensified glycemic control (Bril & Perkins, 2008) .
It is estimated that 65-80% of people with diabetes will die of a cardiovascular event, of which a high proportion will occur without prior signs or symptoms of cardiovascular disease (CVD) (Booth, Kapral, Fung, et al., 2006; Poirier, 2008) . A meta analysis of over 698 000 individual data found that individuals with no history of diabetes, and a fasting glucose between 5.6 and 6.1 mmol/L and between 6.1 and 7.0 mmol/L had an increased risk of coronary heart disease by about 11% and 17% respectively (Emerging Risk Factors Collaboration, 2010). The NDSS estimates that Canadians with diabetes were three times more likely to be hospitalized for ischemic heart disease and myocardial infarctions, than Canadians without diabetes (PHAC, 2009a). The research evidence thus far demonstrates a modest reduction in CVD, specifically myocardial infarction with glucose intensification in people with type 2 diabetes. The modest effect with glucose intensification suggests a wider approach to diabetes management, targeting blood pressure and lipid management is also required (The ADVANCE Collaborative Group, 2008; The ACCORD Study Group, 2008; Gerstein, 2010) .
Risk factors
The most important risk factors for type 2 diabetes are impaired glucose tolerance and/or impaired fasting glucose, or collectively known as prediabetes; in which case glucose levels are above normal targets, but not high enough to diagnosis as diabetes (Ur, Chiasson, Ransom & Rowe, 2008). Gestational diabetes or the delivery of a macrosomic infant (> 9 lbs) are additional risk factors for women. Hypertension, dyslipidemia, abdominal obesity and being overweight are modifiable risk factors for diabetes. Vascular disease, including coronary, cerebral and peripheral, are also risk factors for type 2 diabetes (Ur et al., 2008).
Non-modifiable risk factors include age (> 40 years of age), having a first-degree relative with type 2 diabetes, being a member of a high-risk population (e.g. people of Aboriginal, Hispanic, South Asian, Asian or African descent), or a diagnosis of schizophrenia are considered risk factors for type 2 diabetes. Finally, women with polycystic ovary syndrome are also considered high risk for diabetes (Ur, et al., 2008) . A list of risk factors for type 2 diabetes is included in Appendix 1.
Rationale for screening
Diabetes is a disease that meets several disease screening principles: 1) diabetes represents an important health problem; 2) the natural history of diabetes is understood; 3) there is a recognizable asymptomatic period in which diabetes can be diagnosed; 4) tests are available that can detect the pre-symptomatic stage of diabetes; 5) screening is ongoing and not an isolated event; and 6) treatment after early detection yields greater benefits than in those with delayed treatment. (Engelgau, Narayan & Herman, 2000) . Furthermore, prediabetes is predictive of type 2 diabetes in approximately 50-70% of cases (Canadian Agency for Drugs and Technologies in Health (CADTH), 2009). However, it is important to distinguish between screening and diagnosing. Screening involves attempts to detect asymptomatic disease and screening tests differentiate those at high risk from those at low risk. Screening methods may include simple, noninvasive/invasive and/or stepwise approaches (Calman, 1994; Morrison, 1992; Wilson & Jungner, 1968) . In contrast, tests undertaken in individuals with symptoms presenting in a clinical setting are for diagnostic purposes and do not represent disease screening.
The American Diabetes Association (ADA) and the CDA recommend screening for type 2 diabetes in individuals > 45 years and > 40 years of age respectively, every three years, using a fasting plasma glucose test (Ur, et al., 2008; ADA, 2010) . Adults at high risk for type 2 diabetes should be considered for screening at any age (ADA, 2010). Although the effectiveness of early identification of diabetes through mass screening compared with no screening has yet to be clearly shown, there is fair evidence to identify those at risk for future diabetes, identify, and if required, treat other CVD risk factors (ADA, 2010).
Screening strategies
Historically, screening for type 2 diabetes required fasting blood glucose (FBG) and/or an oral glucose tolerance test (OGTT), which uses both a fasting and a 2 hour post glucose load blood glucose value (Appendix 2). A growing body of literature demonstrates that glycated hemoglobin (A1C), OGTT and FBG are equivalent as predictors of retinopathy and nephropathy development, thus suggesting that A1C, OGTT and FBG may all be valid screening tools for diabetes (Bennett, Guo & Dharmage, 2007) . The screening strategies considered in this review are FBG, OGTT, and A1C. The FBG test (defined as no caloric intake for at least eight hours) is also a component of diagnostic testing and is often preferred because it is faster to perform and more convenient for the patient. The A1C test provides a retrospective average of glycemic control for the previous three months, by measuring the binding glucose to hemoglobin during the life span of red blood cells (Garlick et al., 1983) . The A1C has a sensitivity ranging from 78-81% and a specificity of 79-84% (Bennett et al., 2007) . It is relatively easy to collect, as the A1C test does not require fasting and has a laboratory cost of approximately 6-19 dollars (Cdn) (CADTH, 2009). The A1C test has traditionally been used to monitor long-term glycemic control, adjust therapy and assess risk for the development and progression of complications. In Canada, the A1C test is currently not recommended for screening type 2 diabetes (Ur, et al., 2008) . However, the ADA recommends that the A1C test be used to screen for diabetes and/or assess the risk of future diabetes where appropriate, provided the A1C test is according to the National Glycohemoglobin Standardized Program (NGSP) and traceable to the Diabetes Control and Complications Trial (DCCT) reference assay. An A1C result of > 6.5% would lead to a diagnosis of diabetes (ADA, 2010).
An additional type 2 diabetes screening tool that is currently being piloted is the CANRISK questionnaire; a 16 item survey designed to predict an individual's ten year risk of developing type 2 diabetes (CADTH, 2009). The CANRISK is modeled on the validated Finnish questionnaire, (FINDRISC) and includes questions about family history, body weight, lifestyle and other factors (PHAC, 2009b) . Participants aged 40-75 years are currently piloting this step wise screening approach which does not require laboratory testing, unless an individual is identified as high risk for type 2 diabetes. Currently the CANRISK method is detecting 5% new cases of undiagnosed diabetes and 15% new prediabetes cases, which would otherwise not be detected through FBG tests (PHAC, 2009b) . However, the CANRISK questionnaire is currently being tested for validity across Canada.
The impact of diabetes screening needs to be put into context of costs; to the individual, as well as to the health care system. In Canada, a diagnosis of diabetes incurs individual financial costs ranging from 1,000 to 15,000 dollars annually, as a result of medication use, glucose monitoring, supplies, and complication prevention and management (CDA, 2010). Individuals also bear an emotional cost as a result of the diagnosis; one of anxiety and altered self-perception. Insurability is also an issue for individuals following a diagnosis of diabetes. Although there is limited research examining the adverse effects of screening for diabetes, a decrease in quality of life was not associated with screening (Edelman, Olsen, Dudley, Harris & Oddone, 2002). The health care costs of diabetes management are tremendous, as by 2020, it is estimated that diabetes will cost the Canadian healthcare system 16.9 billion dollars annually (CDA, 2010).
A recent review determined that the A1C test may be the most cost effective screening test for diabetes, as it is convenient and it also reflects post prandial glucose excursions (Waugh, Scotland, McNamee, Gillett, Brennan, Williams, et al., 2007). The OGTT was deemed too expensive and inconvenient, and the FBG test was incapable of detecting individuals with impaired glucose tolerance (Waugh, et al., 2007) . The authors also conclude that screening for diabetes appears to be cost-effective for the 40-70-year age group, but even in the 40-49-year age group, the incremental cost-effectiveness ratio for screening versus no screening was 10,216 pounds or approximately 15,630 (Cdn) dollars per quality-adjusted life-year. However, the authors caution that the cost-effectiveness of screening for type 2 diabetes is determined as much by, if not more than, the degree of glycemic control and future treatment, than by assumptions related to the screening process (Waugh, et al., 2007) .
Interventions/treatments
Individuals with a prediabetes diagnosis are strongly encouraged to undertake lifestyle modifications that include increasing physical activity, altering one's diet and weight loss. It is estimated that a 5% reduction in initial body weight can reduce the risk of progression from prediabetes to type 2 diabetes by approximately 60% (Knowler et al., 2002) . The initiation of pharmaceutical agents such as an alpha glucosidase inhibitor, biguanide or thiazolidinedione may also prevent the progress to type 2 diabetes by 30-60% respectively (Ur, et al., 2008).
The goals of treatment for type 2 diabetes are similar to prediabetes treatment, in that lifestyle modification is a cornerstone of management. Pharmacotherapy plays a more integral part in the 
Previous Reviews and CTFPHC Recommendations
In 1992, although the Expert Committee of the Canadian Diabetes Advisory Board (ECCDAB) did not provide recommendations for type 2 diabetes screening, they did recommend that adults with a FBG test of > 7.8 mmol/L on at least two occasions should be diagnosed with diabetes (ECCDAB, 1992). In 1998, the clinical practice guidelines were updated and provided clear recommendations for the screening of type 2 diabetes, including testing for diabetes using a FBG every three years in adults > 45 years of age. Those at high risk were recommended to be tested earlier and more often (Grade D recommendation, consensus) (Meltzer, Leiter, Daneman, Gerstein, Lau, Ludwig, et al., 1998). In 2003, the CDA's clinical practice expert committee updated the guidelines to include screening for diabetes in adults > 40 years of age, every three years with a FBG test (CDA, 2003) .
In 2005, the CTFPHC published a guideline for the screening of type 2 diabetes mellitus to prevent vascular complications (Feig, et al., 2005) . The following recommendations were made:
There is fair evidence to recommend screening adults with hypertension for type 2 diabetes to reduce the incidence of cardiovascular (CV) events and mortality (Grade B recommendation). There is fair evidence to recommend screening adults with hyperlipidemia for type 2 diabetes to reduce the incidence of CV events and mortality (Grade B recommendation). There is good evidence to recommend treatment of overweight* individuals with impaired glucose tolerance (IGT) with lifestyle interventions to reduce the incidence of diabetes progression (Grade B recommendation). There is insufficient evidence to recommend treatment of overweight* individuals with IGT with metformin or acarbose to reduce the incidence of diabetes progression (Grade I recommendation). There is fair evidence to recommend treatment of overweight* individuals with IGT with acarbose to prevent cardiovascular outcomes and hypertension (Grade B recommendation). To answer key questions 1 and 2 the same search strategy will be implemented, and all searches will be updated to July 2010. To answer contextual questions 1 -7, focused searches for systematic reviews and randomized control trials will be done of the same databases from 2005 to the present. For contextual questions 2-4, observational or epidemiological studies may be included, depending on the availability of data from systematic reviews and randomized controlled trials. The search for cost-effectiveness studies will include simulation modeling for cost-effectiveness and cost-benefit analysis.
Key Questions

Inclusion/ Exclusion Criteria
The following inclusion criteria will be utilized (Norris, et al., 2008) :
Methods:
English language, published randomized controlled trials, observational studies and systematic reviews for the effectiveness or adverse effects of screening and diagnosis of type 2 diabetes will be included.
Population:
Asymptomatic adults 18 years of age or older who are at high risk or average risk for type 2 diabetes complications (Appendix 1) will be included. Non-insulin dependent diabetes will be presumed to be type 2 diabetes. The USPSTF review included adults over the age of 20 years. The search will not be redone for studies including those between the ages of 18-20 years for 2001-July 2007; however, any new reports since July 2007 that studied people 18 years and over will be included.
Interventions:
Screening methods: Studies using the FBG, OGTT and A1C will be considered for this updated review. Screening questionnaires such as the CANRISK and FINRISK will be included in the search to determine if a two phase screening approach is effective.
Comparators:
The comparator for screening will be no screening or studies that compare the screening tests.
Outcomes:
The outcomes will focus on final health outcomes primarily: all cause mortality; cardiovascular mortality; stroke; myocardial infarction; end stage renal disease; angina; blindness; and severe retinopathy. For prediabetes, the intermediate outcome examined was incidence of type 2 diabetes, as this outcome was the primary outcome for the studies included. Outcomes will be prioritized by the Working Group using the GRADE process.
Harms of screening will also be collected. Harms will be prioritized by the Working Group using the GRADE process.
Quality and strength of evidence criteria
The retrieved included studies will be reviewed according to the criteria set out in the CTFPHC Procedure Manual, 2009), Appendices VII and VIII. 
